DUMMYHDLVR - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.6
| Stock Code | DUMMYHDLVR | Market Cap | N/A | Current Price | N/A | High / Low | N/A |
| Stock P/E | N/A | Book Value | N/A | Dividend Yield | N/A | ROCE | N/A |
| ROE | N/A | Face Value | N/A | DMA 50 | N/A | DMA 200 | N/A |
| Chg in FII Hold | N/A | Chg in DII Hold | N/A | PAT Qtr | N/A | PAT Prev Qtr | N/A |
| RSI | N/A | MACD | N/A | Volume | N/A | Avg Vol 1Wk | N/A |
| Low price | N/A | High price | N/A | PEG Ratio | N/A | Debt to equity | N/A |
| 52w Index | N/A | Qtr Profit Var | N/A | EPS | N/A | Industry PE | N/A |
Analysis: Dr. Reddy’s Laboratories (DRREDDY) shows strong fundamentals but faces short-term profit weakness. Current price (1,323 ₹) is above both DMA 50 (1,267 ₹) and DMA 200 (1,257 ₹), confirming bullish momentum. RSI at 59.5 suggests mildly overbought conditions, while MACD (18.8) supports positive momentum. ROCE (25.8%) and ROE (20.3%) are strong, supported by low debt-to-equity (0.13). Quarterly PAT dropped sharply (90.6 Cr. vs 387 Cr.), with profit variation at -89.3%, raising caution. Valuation is reasonable with P/E of 23.8 compared to industry PE of 30.1, and PEG ratio of 0.49 indicates strong growth potential. EPS of 55.6 ₹ adds earnings visibility, though reduced FII interest (-1.20%) is a concern.
Optimal Entry Price: Around 1,300–1,310 ₹ (near DMA support).
Exit Strategy if Holding: Consider booking profits near 1,360–1,380 ₹ unless momentum sustains above 1,380 ₹ resistance.
✅ Positive
- Strong ROCE (25.8%) and ROE (20.3%).
- Low debt-to-equity ratio (0.13) ensures financial stability.
- Valuation attractive with P/E (23.8) below industry average (30.1).
- DII holdings increased (+0.28%), showing domestic investor confidence.
⚠️ Limitation
- Quarterly PAT decline (90.6 Cr. vs 387 Cr.) with -89.3% variation.
- FII holdings decreased (-1.20%), showing reduced foreign interest.
- RSI at 59.5 indicates mildly overbought conditions.
📰 Company Negative News
- No major negative news reported, but sharp profit decline and reduced foreign interest are concerns.
🌟 Company Positive News
- Strong efficiency metrics (ROCE and ROE).
- Valuation attractive compared to industry peers.
- Domestic institutional investors increased their stake.
🏭 Industry
- Industry P/E at 30.1 suggests Dr. Reddy’s trades at a discount.
- Pharmaceutical sector remains resilient with global demand for generics and APIs.
📌 Conclusion
Dr. Reddy’s Laboratories is a good candidate for swing trading. Entry around 1,300–1,310 ₹ offers a favorable risk-reward setup, while exit near 1,360–1,380 ₹ is advisable unless momentum sustains above 1,380 ₹. Strong fundamentals and attractive valuation are positives, but sharp profit decline and reduced foreign interest warrant cautious optimism.
Would you like me to expand this with a technical chart outlook, peer comparison, or sector growth analysis?